

AQUINOX PHARMACEUTICALS, INC  
Form 8-K  
May 13, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 13, 2014**

**Aquinox Pharmaceuticals, Inc.**

**(Exact name of Registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36327**  
**(Commission**  
  
**File Number)**  
**450 887 Great Northern Way,**  
  
**Vancouver, B.C.**

**98-0542593**  
**(IRS Employer**  
  
**Identification No.)**

**Canada, V5T 4T5**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (604) 629-9223**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition**

On May 13, 2014, Aquinox Pharmaceuticals, Inc. (the Company) issued a press release announcing its financial results for the first quarter ended March 31, 2014. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this current report on Form 8-K and the press release attached as Exhibit 99.1 hereto is being furnished, but shall not be deemed filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (Exchange Act), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <b>Number</b> | <b>Description</b>  |
|---------------|---|
| 99.1          | Press Release of Aquinox Pharmaceuticals, Inc. dated May 13, 2014 |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Aquinox Pharmaceuticals, Inc.

Date: May 13, 2014

By: /s/ Kamran Alam  
Name: Kamran Alam  
Title: Chief Financial Officer

**INDEX TO EXHIBITS**

| <b>Number</b> | <b>Description</b>  |
|---------------|---|
| 99.1          | Press Release of Aquinox Pharmaceuticals, Inc. dated May 13, 2014 |